Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine dose-ranging with metoclopramide for gastric residual volume in ICU trauma patients
IRCT20160523028008N21Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of neostigmine and metoclopramide in enteral feeding intolerance (EFI) and Increased gastric residual volume (GRV) (4 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Gastric residual volume at 12 hours. Started Mar 2022; status: completed.
02
Drugs
neostigminemetoclopramide
03
Conditions
enteral feeding intolerance (EFI)Increased gastric residual volume (GRV)
Beyond the preview
Go deeper on IRCT20160523028008N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160523028008N21.